Are investors shorting XTL Biopharmaceuticals?

XTL Biopharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 437,200 shares, an increase of 21,760.0% from the March 15th total of 2,000 shares. Based on an average daily volume of 720,600 shares, the days-to-cover ratio is presently 0.6 days. View XTL Biopharmaceuticals' Short Interest .

When is XTL Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our XTLB earnings forecast .

When did XTL Biopharmaceuticals' stock split?

XTL Biopharmaceuticals's stock reverse split on the morning of Friday, February 10th 2017. The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of XTL Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XTL Biopharmaceuticals investors own include Sorrento Therapeutics (SRNE) , Supernus Pharmaceuticals (SUPN) , VIVUS (VVUS) , Akari Therapeutics (AKTX) , CymaBay Therapeutics (CBAY) , Catalyst Pharmaceuticals (CPRX) , Exelixis (EXEL) , Gilead Sciences (GILD) , Novus Therapeutics (NVUS) and Regulus Therapeutics (RGLS) .

NASDAQ:XTLB

XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free XTLB Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $2.41
▼
$2.50
50-Day Range: $3.43
▼
$5.20
52-Week Range: $1.73
▼
$6.69

Volume: 11,936 shs
Average Volume: 1.58 million shs
Market Capitalization: $13.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Earnings Headlines Short Interest Social Media

Get XTL Biopharmaceuticals alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

XTLB Stock News Headlines

March 20, 2024 | msn.com

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03%

March 20, 2024 | msn.com

US Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top Views

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 20, 2024 | markets.businessinsider.com

Dow Surges 350 Points; Fed Holds Rates Steady

March 20, 2024 | markets.businessinsider.com

Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher

March 20, 2024 | globenewswire.com

XTL To Aquire The Social Proxy

February 17, 2024 | investing.com

XTL Biopharmaceuticals Ltd ADR (XTLB)

October 23, 2023 | finance.yahoo.com

XTL Biopharmaceuticals Ltd (H2K2.MU)

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

October 23, 2023 | finanznachrichten.de

XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

October 21, 2023 | finanznachrichten.de

XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

October 20, 2023 | finance.yahoo.com

XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

October 20, 2023 | finance.yahoo.com

XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

October 1, 2022 | seekingalpha.com

XTLB XTL Biopharmaceuticals Ltd.

August 8, 2022 | reuters.com

X T L Biopharmaceuticals Ltd

July 23, 2022 | seekingalpha.com

LIFE, TBLT and XTLB among pre market gainers

December 15, 2021 | uk.finance.yahoo.com

XTL Biopharmaceuticals Ltd. (XTLB)

See More Headlines

Receive XTLB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 5/21/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:XTLB
CUSIP: N/A
CIK: 1023549
Web: www.xtlbio.com
Phone: (729) 955-7080
Fax: 972-3611-6605
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.42)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -73.05%
Return on Assets: -68.83%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.09
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.73 per share
Price / Book: 3.34

Miscellaneous

Outstanding Shares: 5,450,000
Free Float: 3,869,000
Market Cap: $13.30 million
Optionable: Not Optionable
Beta: 1.21

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Shlomo Spokone Shalev
Chief Executive Officer & Executive Director
Itay Weinstein
Chief Financial Officer
Daphna Paran
Medical Director

Key Competitors

View All Competitors

XTLB Stock Analysis - Frequently Asked Questions

Are investors shorting XTL Biopharmaceuticals?: XTL Biopharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 437,200 shares, an increase of 21,760.0% from the March 15th total of 2,000 shares. Based on an average daily volume of 720,600 shares, the days-to-cover ratio is presently 0.6 days.
View XTL Biopharmaceuticals' Short Interest.
When is XTL Biopharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our XTLB earnings forecast.
When did XTL Biopharmaceuticals' stock split?: XTL Biopharmaceuticals's stock reverse split on the morning of Friday, February 10th 2017. The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.
What other stocks do shareholders of XTL Biopharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other XTL Biopharmaceuticals investors own include Sorrento Therapeutics (SRNE), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Akari Therapeutics (AKTX), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), Gilead Sciences (GILD), Novus Therapeutics (NVUS) and Regulus Therapeutics (RGLS).

This page (NASDAQ:XTLB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis

About XTL Biopharmaceuticals

XTLB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

XTLB Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info